Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN125 +/- SYN004 in Solid Tumors
NCT04363242Phase 1Unknown
- Sponsor
- Xingmeng Biopharmaceutical
- Start
- Apr 2020
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYN125 in solid tumor and epithelial carcinoma (2 arms), sponsored by Xingmeng Biopharmaceutical. Primary endpoint: Incidence of dose-limiting toxicities at Day 28. Status: unknown.
02
Drugs
SYN125
03
Conditions
solid tumorepithelial carcinoma
Beyond the preview
Go deeper on NCT04363242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04363242.